ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.Immunotherapy · 2025Review
- Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.Nature communications · 2024Article
- Chimerization of the Anti-Viral CD8Research square · 2023Article
- Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses.Molecular therapy oncolytics · 2023Article
- Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches.Breast cancer (Tokyo, Japan) · 2023Review
- Synergy betweenJournal for immunotherapy of cancer · 2021Article
- Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.Nature communications · 2021Article
- APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy.Nature communications · 2020Article
- Oncolytic Viruses: Priming Time for Cancer Immunotherapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019Review
- Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity.Journal for immunotherapy of cancer · 2019Article
- Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference.Translational vision science & technology · 2019Article
- PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.The Journal of clinical investigation · 2018Article
- Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.The Journal of general virology · 2017Article
- Oncolytic Virotherapy: A Contest between Apples and Oranges.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Review
- Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Frontiers in immunology · 2017Review
- Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.Frontiers in oncology · 2017Review
- TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.OncoimmunologyArticle
- Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses against both viral and tumor antigens. We have shown that therapy with vesicular stomatitis virus (VSV) engineered to express a tumor-associated antigen activates antigen-specific adoptively transferred T cells (adoptive cell therapy, ACT) in vivo to generate effective therapy. The overall goal of this study was to phenotypically characterize the immune response to VSV+ACT therapy and use the information gained to rationally improve combination therapy. We observed rapid expansion of blood CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.